CHMP vurderede desuden, at udskillelsen af mirtazapin kan reduceres hos patienter med moderat til svær nyrebeskadigelse (kreatinin- udskillelse < 40 ml/ min.).
Additionally, the CHMP considered that the clearance of mirtazapine may be decreased in patients with moderate to severe renal impairment (creatinine clearance < 40 ml/ min).